Corporate Management
|
Eric L. Dobmeier |
|
|
Clay B. Siegall, Ph.D. President and Chief Executive
Officer
Clay Siegall co-founded Seattle Genetics in 1998
and is the company’s President, Chief Executive Officer and a member of the
Board of Directors. Under his leadership, Seattle Genetics
has developed a diverse portfolio of clinical and preclinical product candidates
targeting a variety of cancer and autoimmune indications. The company is also a
leader in antibody technologies, notably its antibody-drug conjugate (ADC)
platform. Dr. Siegall has guided Seattle Genetics’
capital-raising activities, securing more than $330 million through public and
private financings, including the company’s initial public offering in 2001. In
addition, the company has entered into multiple strategic collaborations,
including an exclusive worldwide collaboration agreement with Genentech for
dacetuzumab (SGN-40)
valued at more than $860 million,
and several ADC collaborations including with Genentech, MedImmune, CuraGen, Bayer,
Progenics and Daiichi Sankyo that have generated more than $65 million since 2001.
Prior to co-founding Seattle Genetics, Dr. Siegall
was with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to
1997 and the National Cancer Institute, National Institutes of Health from 1988
to 1991. He serves on the Board of Directors of Alder BioPharmaceuticals, a
private biotechnology company, and the Washington Biotechnology and
Biomedical Association (WBBA), as well as on the Board of Governors of the
Fred Hutchinson Cancer Research Business Alliance. He received a Ph.D.
in Genetics from George Washington University and a B.S. in Zoology from the
University of Maryland.
 |
Eric L. Dobmeier,
Chief Business Officer
Eric Dobmeier joined Seattle Genetics in March 2002. He manages the company's business development, legal, corporate communications,
strategic marketing and project management
groups. While at Seattle Genetics,
he has led negotiation and completion of multiple corporate alliances, including
the worldwide collaboration agreement with Genentech on dacetuzumab (SGN-40), the in-license of
lintuzumab (SGN-33) from PDL BioPharma and ADC
collaborations with CuraGen, Progenics, Bayer, MedImmune, Daiichi Sankyo and Agensys. He has also participated in raising over $300
million in equity financing for Seattle Genetics.
Prior to joining the company, Mr. Dobmeier was with the law firms of Venture Law
Group and Heller Ehrman White & McAuliffe, where he represented technology
companies in connection with public and private financings, mergers &
acquisitions and corporate partnering transactions. Mr. Dobmeier holds a law degree from Boalt Hall
School of Law, University of California, Berkeley and an undergraduate degree
from Princeton University.
 |
Thomas C. Reynolds, M.D., Ph.D., Chief Medical
Officer
Tom Reynolds joined Seattle Genetics in March
2007. As Chief Medical Officer, he leads clinical and regulatory activities
across the company’s product portfolio. Dr. Reynolds has more than 15 years of
biotechnology drug development experience, from preclinical development through
the FDA approval process. Before joining Seattle Genetics,
he was at Zymogenetics from 2002 to 2007, most recently as Vice President,
Medical Affairs, where he oversaw the clinical development and BLA filing of
rhThrombin and led the Medical Affairs department. Previously, he held various
positions at Targeted Genetics including Vice President, Clinical Affairs, and
before that was at Somatix Therapy (acquired by Cell Genesys in 1997). Dr.
Reynolds holds a B.A. in Chemistry from Dartmouth College and both a Ph.D. in
Biophysics and M.D. from Stanford University.
 |
Todd E. Simpson, Chief Financial
Officer
Todd Simpson joined Seattle Genetics in October
2005, bringing extensive industry experience from senior financial positions
with several public biotechnology companies. Prior to joining
Seattle Genetics, he served as Vice President of Finance and
Administration and Chief Financial Officer at Targeted Genetics since October
2001. Previously, he was Vice President, Finance and Administration and Chief
Financial Officer of Aastrom Biosciences. From 1992 to 1996, he served in
financial roles at Integra Life Sciences Corporation and Telios Pharmaceuticals,
Inc. (which was acquired by Integra in 1995). Mr. Simpson practiced public
accounting with the firm of Ernst & Young LLP from 1983 to 1992, primarily
focused in the life sciences and technology practices. He is a certified public
accountant and received his B.S. in accounting and computer science from Oregon
State University.
 |
Christopher Pawlowicz, Senior Vice President, Human
Resources
Christopher Pawlowicz joined Seattle Genetics in
September 2008. He has more than 25 years of human resources experience
principally in the pharmaceutical industry. Prior to Seattle Genetics,
Mr. Pawlowicz was Senior Vice President, Human Resources and Administration at
MedPointe Pharmaceuticals, a private equity-backed specialty pharma company
where he was part of the turnaround team that successfully restructured and sold
the business to Meda Pharmaceuticals. Before that, he was Corporate Vice
President, Human Resources at Express Scripts, the nation’s third largest
pharmacy benefit management company. Mr. Pawlowicz’s career has also included
senior human resources positions at Pharmacia, Searle and Monsanto. Highlights
include the global launch of Celebrex, the start up of biotechnology commercial
teams in plant sciences, support of high growth commercial investments in Latin
America, Europe and Asia, and the post-merger integration of numerous companies.
He graduated summa cum laude with a B.A. in Economics from Benedictine College,
and received his M.A., Labor and Industrial Relations from the University of
Illinois – Urbana-Champaign.
 |
Morris Z. Rosenberg, D.Sc., Senior Vice President, Development
Morris Rosenberg joined Seattle Genetics in July
2001. Prior to joining the company, he was with Eli Lilly & Company (1998-2001), Biogen Incorporated (1990-1998) and Invitron Corporation (1987-1990). Dr. Rosenberg received a D.Sc. in Chemical Engineering, an M.S. and B.S. in Chemical Engineering, and a B.A. in Biology from Washington University in St. Louis, Missouri. While at Biogen he participated in the development of the manufacturing process for the multiple sclerosis treatment
Avonex. Most recently at Eli Lilly, as Head of Cell Culture and Fermentation Development, Dr. Rosenberg led efforts in the development of several cell culture processes including for the sepsis therapeutic
Xigris.
 |
Elaine Waller, PharmD, Senior Vice
President, Regulatory Affairs
Elaine Waller, PharmD, joined Seattle Genetics in September 2008, bringing more
than 20 years of experience in regulatory affairs and clinical research. Prior
to joining Seattle Genetics, Dr. Waller was with Sonus Pharmaceuticals, where
she served as Senior Vice President, Regulatory Affairs/Quality Assurance and
Clinical Research until its merger with OncoGenex Pharmaceuticals in August
2008. Before that, she was Chief Operating Officer at Radiant Research, a
clinical site management organization. Dr. Waller’s previous experience includes
senior positions in regulatory affairs and clinical research at Hoechst Marion
Roussel and Marion Merrell Dow, predecessor companies to sanofi-aventis. She
began her career in academia at the University of Texas at Austin where she held
teaching positions in both graduate and undergraduate pharmacy education and was
Assistant Director of Clinical Research at the Drug Dynamics Institute. Dr.
Waller received a B.S. in Pharmacy and a Doctor of Pharmacy from the University
of Missouri – Kansas City and an M.B.A. from Rockhurst College.
 |
Jonathan Drachman, M.D., Vice
President, Early Clinical Development
Jonathan Drachman joined Seattle Genetics in
November 2004. He oversees the activities involved in transitioning the
company’s antibody-based therapeutics from preclinical into clinical
development, including clinical pharmacology, bioanalytical development and
early-stage clinical trial execution. Prior to joining
Seattle Genetics, Dr. Drachman was Associate Professor in the Hematology
Division, Department of Medicine at the University of Washington in Seattle,
where he remains a Clinical Associate Professor of Medicine. He also served as
Senior Investigator in the Division of Research and Education and Medical
Director of the Umbilical Cord Blood Program at the Puget Sound Blood Center.
Dr. Drachman received a B.A. in biochemistry from Harvard University and an M.D.
from Harvard Medical School. He completed his residency in Internal Medicine and
fellowship in Medical Oncology at the University of Washington in Seattle.
 |
Iqbal S. Grewal, Ph.D., Vice
President, Preclinical Therapeutics
Iqbal Grewal
joined Seattle Genetics in October 2004. He
manages the company’s molecular oncology and immunology, translational biology
and pharmacology and toxicology functions,
including the planning and execution of studies to advance
preclinical programs and support clinical development activities. Prior to joining Seattle Genetics,
Dr. Grewal was with
Genentech as a Senior Scientist in the Department of Immunology. He joined
Genentech in May 1998, where he managed discovery research programs responsible
for identifying and validating novel molecules for therapeutic use in the areas
of oncology and autoimmune disease. In addition, he was a project leader
on teams that conducted extensive studies of preclinical candidates for product
development. Prior to Genentech, Dr. Grewal worked at Yale University School
of Medicine. Before that, he held various research positions at the University
of California, Los Angeles (UCLA). Dr. Grewal holds a B.S. in Biology and Chemistry from
Panjab University in India, a M.S. in Immunobiology from the University of Aberdeen
in the United Kingdom and a Ph.D. in Immunology from UCLA. He has published over 80 manuscripts
and co-authored several patent applications.
 |
Peter D. Senter, Ph.D. Vice President, Chemistry
Peter Senter joined Seattle Genetics in August 1998.
He leads the company's chemistry department, which carries out research in
antibody-drug conjugate technologies, including the development of potent drug
payloads, novel linker systems, conjugation methodology and mechanism of action
studies. Prior to joining the company, Dr. Senter was with Cytokine Networks, Inc., the Bristol-Myers Squibb Pharmaceutical Research Institute and the Dana-Farber Cancer Institute, Harvard Medical School. Dr. Senter received a Ph.D. in Chemistry from the University of Illinois, and an A.B. in Biochemistry from the University of California, Berkeley. He is the
Senior Editor of Bioconjugate Chemistry and serves on the Editorial Board of four scientific journals. Dr. Senter is an Affiliate Professor of Bioengineering at the University of Washington. His research interests include targeted drug delivery, protein chemistry and biochemistry, and anti-cancer drug design. Dr. Senter has authored
more than 100 scientific publications and holds more than 20 patents.
 |
Eric Sievers, M.D., Senior Medical Director
Eric Sievers joined Seattle Genetics in July 2006. He is responsible for
directing, planning and executing clinical development activities of several of
the company’s therapeutic programs. From 2003 to 2006, Dr. Sievers served as
Medical Director at Zymogenetics supervising the oncology development of
interleukin-21 and Atacicept. He performed his training in pediatric hematology
and oncology at the University of Washington and the Fred Hutchinson Cancer
Research Center, and served on the faculty of both institutions for over a
decade. His academic research focused on improving treatment outcomes for
patients with acute myeloid leukemia by defining the safety and efficacy of
gemtuzumab ozogamicin (Mylotarg®) and evaluating novel flow cytometric
techniques to predict leukemic recurrence. He is a member of the American
Society of Hematology, American Society of Clinical Oncology and American
Association for Cancer Research and is certified by the American Board of
Pediatrics.